Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Current Assets (2022 - 2025)

Historic Current Assets for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $6.3 million.

  • 60 Degrees Pharmaceuticals' Current Assets fell 844.26% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 844.26%. This contributed to the annual value of $5.4 million for FY2024, which is 2563.05% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Current Assets of $6.3 million as of Q3 2025, which was down 844.26% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Current Assets registered a high of $8.9 million during Q3 2023, and its lowest value of $1.1 million during Q4 2022.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Current Assets value was $5.7 million (recorded in 2023), while the average stood at $5.7 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 55901.38% in 2023, then crashed by 3368.56% in 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Current Assets (Quarter) stood at $1.1 million in 2022, then skyrocketed by 559.01% to $7.2 million in 2023, then fell by 25.63% to $5.4 million in 2024, then grew by 17.13% to $6.3 million in 2025.
  • Its Current Assets was $6.3 million in Q3 2025, compared to $3.8 million in Q2 2025 and $5.7 million in Q1 2025.